The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety of angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients with bladder and upper tract malignancies undergoing platinum-based chemotherapy: A retrospective study.
 
Spencer Gibson
No Relationships to Disclose
 
Dalia Kaakour
No Relationships to Disclose
 
Omid Yazdanpanah
No Relationships to Disclose
 
Benjamin Lee
No Relationships to Disclose
 
Nazmul Hasan
No Relationships to Disclose
 
Garo Hagopian
No Relationships to Disclose
 
Brian Warnecke
No Relationships to Disclose
 
Desiree Rafizadeh
No Relationships to Disclose
 
Eva Zhao
No Relationships to Disclose
 
Garrett Harada
No Relationships to Disclose
 
Steven Seyedin
No Relationships to Disclose
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AimedBio; AstraZeneca; aveo; Bayer; Bicycle Therapeutics; Eisai; Exelixis; Sumitomo Dainippon Pharma Oncology
Speakers' Bureau - Amgen; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Myovant Sciences; Pfizer; Sanofi
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eikon Therapeutics; Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); navir (Inst); Novartis (Inst); POINT Biopharma (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Janssen
 
Nataliya Mar
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Eisai; Merck
Research Funding - Gilead Sciences